A key trend poised to reshape the sector is the burgeoning adoption of cloud-based solutions. Veeva Systems, with its cloud-based software for the global life sciences industry, is leading the charge in this domain. The shift towards cloud computing is driven by the need for scalable, secure and flexible data management solutions that can support the complex workflows of pharmaceutical companies. This trend is anticipated to enhance collaboration across research and development, clinical trials, and regulatory processes, thereby accelerating the pace of drug development and approval.
Another significant technology trend is the integration of artificial intelligence (AI) and machine learning (ML) within pharmaceutical operations, from drug discovery to patient engagement strategies. AI-driven analytics are transforming data into actionable insights, improving decision-making processes and personalizing patient care. Particularly, AI is revolutionizing the drug discovery process by identifying potential drug candidates at an unprecedented speed and accuracy. While ML algorithms are optimizing clinical trial designs and patient recruitment strategies, making them more efficient and cost-effective. The Veeva 2024 project is expected to leverage these AI capabilities to drive innovation and efficiency in the pharmaceutical industry.
The life science analytics market is expected to be $9.8 billion in 2023. If the market grows at a CAGR of 24 percent from 2023 to 2030, the market value in 2030 could be between $143.8 billion and $538.3 billion. The rapid advancements in data, technology and medicine are reasons for this growth.
This edition of Pharma Tech Outlook brings insights into the latest developments in Veeva and how companies align with the latest trends for greater transparency and actionable insights in the life sciences sector.
It features a thought leadership article from Stefania Alvino, Head of Digital Innovation - Customer Experience Excellence Department & DSPACE, Daiichi Sankyo, who sheds light on how digital health is transforming healthcare with personalized treatments, enhanced patient involvement and improved diagnostics through AI, ultimately aiming for better treatment outcomes and accessibility. It also features an article from Jennifer Perrin, Associate Director, Quality & Compliance at MMS Holdings Inc., who emphasizes the importance of how outsourcing quality functions in pharmaceuticals saves costs and provides expertise, especially for smaller firms.
In this edition of Pharma Tech Outlook, we also bring you a thought leadership article from Sophie Toya, MD, Associate Director, Clinical Development, Dompé. She highlights that acute respiratory distress syndrome, characterized by hypoxemic respiratory failure due to lung injury is significantly influenced by neutrophil extracellular traps. Another article from Tony Johnson, Senior Director, Global Clinical Quality Assurance, Mallinckrodt Pharmaceuticals, specifies the transformative impact of technologies like blockchain and AI on quality systems and advocates for patient-centric approaches, proactive measures and collaboration to enhance clinical research and compliance.
In this edition featuring the Top Veeva Solutions Providers 2024, we hope you find the right partner to meet your organization’s needs.
